Objectives
Most first-time biomedical research grant applications are not funded. In the challenging research funding climate, resubmitting a grant application is a necessary task for scientists. Identifying which factors influence their decision to resubmit and the success of resubmissions will inform funders and applicants. However, data on resubmissions are fragmented and under-reported. In this scoping review, we aimed to summarise (1) the outcomes of resubmitting biomedical research grant applications and (2) the demographic characteristics of scientists who resubmitted grant applications.
Design
Scoping review with reporting informed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Data sources
MEDLINE, CINAHL, EMBASE, Cochrane Central Registrar of Controlled Trials CENTRAL, PsycINFO, Web of Science and grey literature sources were searched through November 2022.
Eligibility criteria
We included peer-reviewed and grey literature records from the biomedical sciences that reported outcomes of the resubmission process (eg, resubmission success rate, rate of resubmission) and information about the scientists who resubmit grant applications (eg, sex, race, career stage).
Data extraction and synthesis
Data were extracted independently by two reviewers. The data were cross-referenced and any conflicts were resolved via consensus. Data were summarised descriptively and presented in tables and figures.
Results
Resubmissions represented a substantial proportion of applications (lowest prevalence rate: 4%; highest prevalence rate: 56%) in a given funding cycle and were reliably more successful than first-time applications (lowest success rate: 16%; highest success rate: 82%)—a phenomenon associated with several sociodemographic, institutional and project-related factors. There was conflicting evidence about the relationship of sociodemographic-related, institution-related and project-related factors to resubmission likelihood and success.
Conclusion
The resubmission process is a time-consuming and often frustrating experience for researchers. Our review identified opportunities to streamline and improve the process to enhance the biomedical research landscape.